Skip to main content
OpenTrials
Completed

NCT Number: NCT00191113

Somatropin Treatment to Final Height in Turner Syndrome

A randomized, controlled trial in girls with Turner syndrome at least 7 years old and younger than 13 at study entry, to determine the efficacy and safety of Humatrope (somatropin) treatment in promoting linear growth to final height.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Turner Syndrome Bone Diseases Bone Diseases, Developmental Cardiovascular Abnormalities Cardiovascular Diseases Chromosome Disorders Congenital Abnormalities Congenital, Hereditary, and Neonatal Diseases and Abnormalities Disease Disorders of Sex Development Dwarfism Endocrine System Diseases Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genetic Diseases, Inborn Gonadal Disorders Gonadal Dysgenesis Heart Defects, Congenital Heart Diseases Male Urogenital Diseases Musculoskeletal Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Sex Chromosome Disorders Sex Chromosome Disorders of Sex Development Syndrome Urogenital Abnormalities Urogenital Diseases

Age range

7 year–13 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 3

Primary location

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri 9 am - 5 pm Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Calgary, Alberta, Canada

Loading trial locations.

About this study

A randomized, controlled trial of Humatrope (somatropin) treatment in girls with Turner syndrome at least 7 years old and younger than 13 at study entry.

Core study objectives are to determine the efficacy of Humatrope in promoting linear growth to final height in girls with Turner syndrome, and to assess the safety of this treatment. Core study completion criteria (protocol final height) are that the patient has both a height velocity < 2 cm per year and a bone age of 14 years or greater.

Addendum 1 provides the option of Humatrope treatment to patients who were randomized to the Control arm of the Core study and who discontinued from the study on or after December 19, 1997.

Addendum 2 objectives are: 1) to collect true final height data; 2) to evaluate hearing, tympanic membrane function and other specific areas of interest with respect to the safety of growth hormone therapy in Turner syndrome; 3) to evaluate pancreatic beta cell function (glucose metabolism) in patients previously enrolled in the Core study.

Addendum 3 objective is to determine the parental origin of the retained X chromosome of an appropriate subset of patients currently or previously enrolled in the Core study, and to determine whether this parental origin holds any predictive value for spontaneous growth or for response to growth hormone therapy.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • girl with Turner syndrome
  • prepubertal, Tanner stage I breast
  • height velocity less than 6 cm/year and height less than or equal to the tenth percentile for sex and age in general population
  • at least 6 months (preferably 12 months) of accurate height measurements available for calculation of pre-study height velocity
  • if thyroxine deficient, to have received replacement therapy, and for six months prior to enrollment have had normal thyroid function tests

Exclusion criteria

  • prior treatment with growth hormone
  • presence of a Y component in karyotype with gonads in situ
  • diabetes mellitus

Treatment and study plan

Somatropin

Drug

0.05 mg/kg/dose by subcutaneous injection 6 times per week, until Core study completion criteria are met (protocol final height).

Other names: Humatrope, Growth hormone

ethinyl estradiol

Drug

escalating doses 2.5-20.0 mcg tablets daily after age 13 and at least one year on study, continuing until Core study completion criteria are met.

Medroxyprogesterone Acetate

Drug

10 mg tablets, ten days monthly, after age 15, continuing until Core study completion criteria are met.

Primary outcomes

  1. Height Standard Deviation Score (SDS) (National Center for Health Statistics [NCHS]), Change From Baseline to Last Measurement, As Randomized Population

    Time frame: Baseline, and end of 4-year addendum

    Value analyzed is change from baseline to the most mature height measurement available. The terms Standard Deviation Score (SDS) and National Center for Health Statistics (NCHS) were defined in baseline characteristics. Greater height SDS values indicate greater height; positive values of change from baseline indicate increased height.

  2. Height Standard Deviation Score (SDS) (National Center for Health Statistics [NCHS]), Last Measurement After Attainment of Final Height

    Time frame: at completion of core study, or at end of 4-year addendum

    SDS report the number of standard deviations from the mean for age and sex for an individual measurement (normal range: -2 to +2 SDS). Height SDS [NCHS] uses the NCHS US general female population reference height values for age (Kuczmarski RJ et al. 2000) as the population mean and standard deviation. Calculation of Height SDS is provided in Height SDS [Lyon] description (Baseline). Since data reported by Kuczmarski RJ et al provides US general female population standards, values of Height SDS [NCHS] for untreated patients with Turner syndrome tend to be below zero e.g, -2.0 to -4.0 SDS.

Secondary outcomes

  1. Height Standard Deviation Score (SDS) (National Center for Health Statistics [NCHS]), Change From Baseline, As-Treated Population

    Time frame: every 3 months during core study, and at start and end of 4-year addendum

    Value analyzed is change from baseline to the most mature height measurement available. The terms Standard Deviation Score (SDS) and National Center for Health Statistics (NCHS) were defined in baseline characteristics. Greater height SDS values indicate greater height; positive values of change from baseline indicate increased height.

  2. Height (Centimeters [cm])

    Time frame: every 3 months during core study, and at start and end of 4-year addendum

    Most mature measurement available, at or after attainment of Final Height.

  3. Number of Participants With an Abnormal Pure Tone Audiometry, Audiologist Assessment

    Time frame: at completion of core study or beginning of addendum

  4. Number of Participants With Abnormal Speech Audiometry, Audiologist Assessment

    Time frame: at completion of core study or beginning of addendum

  5. Number of Participants With Abnormal Impedance Tympanometry, Audiologist Assessment

    Time frame: at completion of core study or beginning of addendum

  6. Number of Participants With Hearing Loss, Audiologist Assessment

    Time frame: at completion of core study or beginning of addendum

    Sensorineural Hearing Loss (SNHL)=air conduction threshold >20 dB HL and air-bone gap ≤10 dB HL; Conductive Hearing Loss (CHL)= air conduction threshold >20 dB HL, bone conduction threshold ≤20 dB HL and air-bone gap >10 dB HL; Mixed Hearing Loss (MHL) = evidence of SNHL as defined above and CHL as defined above, in the same ear; Unspecified Hearing Loss (UHL)= abnormal hearing with none of SNHL, CHL, or MHL present.

  7. Fasting Glucose, Change From Baseline

    Time frame: At core study baseline, and at end of 4-year addendum

    Change from core study baseline to addendum 2 maximum.

  8. Maximum Fasting Glucose Value

    Time frame: At start and through end of 4-year addendum (up to an additional 2 years)

    Maximum measured value over addendum. In special cases an additional measurement is taken at 2 years.

  9. Number of Participants With Any Abnormal Fasting Glucose Value

    Time frame: At start and through end of 4-year addendum

    Indicates if patient had any measured value exceeding threshold of normality at any visit during addendum. Abnormal Fasting Glucose=Fasting Glucose >=100 milligrams per deciliter (mg/dL).

  10. Maximum Fasting Insulin Values

    Time frame: At start and through end of 4-year addendum (up to an additional 2 years)

    Maximum measured value over addendum. In special cases an additional measurement is taken at 2 years.

  11. Number of Participants With Any Abnormal Fasting Insulin Value

    Time frame: At start and through end of 4-year addendum

    Indicates if patient had any measured value exceeding threshold of normality at any visit during addendum. Abnormal Fasting Insulin = Fasting Insulin >=35 micro International Units per milliliter (uIU/mL).

  12. Minimum Fasting Glucose/Insulin Ratio Values

    Time frame: At start and through end of 4-year addendum (up to an additional 2 years)

    Minimum measured value over addendum. In special cases an additional measurement is taken at 2 years.

  13. Number of Participants With Any Abnormal Fasting Glucose/Insulin Ratio Value

    Time frame: At start and through end of 4-year addendum

    Indicates if patient had any measured value below threshold of normality at any visit during addendum. Abnormal Fasting Glucose/Insulin Ratio = Fasting Glucose/Insulin Ratio <=4.5 milligrams per 10^-4 Units (mg/10^-4U).

  14. Glycosylated Hemoglobin, Change From Baseline

    Time frame: At core study baseline, and at end of 4-year addendum

    Change from core study baseline to addendum 2 maximum.

  15. Maximum Glycosylated Hemoglobin

    Time frame: At start and through end of 4-year addendum (up to an additional 2 years)

    Maximum measured value over addendum. In special cases an additional measurement is taken at 2 years.

  16. Number of Participants With Any Abnormal Glycosylated Hemoglobin (HbA1c) Value

    Time frame: At start and through end of 4-year addendum

    Indicates if patient had any measured value exceeding threshold of normality at any visit during addendum. Abnormal Glycosylated Hemoglobin = HbA1c ≥6.8% (up until 11-May-1998); and then HbA1c ≥6.1% (from 19-May-1998 onwards).

Sponsors and collaborators

Lead sponsor

Eli Lilly and Company

Industry

Registry information

Official study title

Humatrope Treatment to Final Height in Turner's Syndrome

Acronym: GDCT

Important dates

Study start
1989
Primary completion
2007
Study completion
2007
First posted
Sep 19, 2005
Registry last updated
Jan 27, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.